153 related articles for article (PubMed ID: 18224273)
21. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).
Licht C; Heinen S; Józsi M; Löschmann I; Saunders RE; Perkins SJ; Waldherr R; Skerka C; Kirschfink M; Hoppe B; Zipfel PF
Kidney Int; 2006 Jul; 70(1):42-50. PubMed ID: 16612335
[TBL] [Abstract][Full Text] [Related]
22. MPGN II--genetically determined by defective complement regulation?
Licht C; Schlötzer-Schrehardt U; Kirschfink M; Zipfel PF; Hoppe B
Pediatr Nephrol; 2007 Jan; 22(1):2-9. PubMed ID: 17024390
[TBL] [Abstract][Full Text] [Related]
23. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type 1 associated with hepatitis C treated successfully with steroids and antiviral therapy: a case report and review of literature.
Ahmed MS; Wong CF; Shawki H; Kapoor N; Pandya BK
Clin Nephrol; 2008 Apr; 69(4):298-301. PubMed ID: 18397706
[TBL] [Abstract][Full Text] [Related]
24. Cyclosporin A treatment for membranoproliferative glomerulonephritis type II.
Kiyomasu T; Shibata M; Kurosu H; Shiraishi K; Hashimoto H; Hayashidera T; Akiyama Y; Takeda N
Nephron; 2002 Jul; 91(3):509-11. PubMed ID: 12119488
[TBL] [Abstract][Full Text] [Related]
25. Factor H genotype-phenotype correlations: lessons from aHUS, MPGN II, and AMD.
Goodship TH
Kidney Int; 2006 Jul; 70(1):12-3. PubMed ID: 16810287
[TBL] [Abstract][Full Text] [Related]
26. A prolonged course of Group A streptococcus-associated nephritis: a mild case of dense deposit disease (DDD)?
Sawanobori E; Umino A; Kanai H; Matsushita K; Iwasa S; Kitamura H; Oda T; Yoshizawa N; Sugita K; Higashida K
Clin Nephrol; 2009 Jun; 71(6):703-7. PubMed ID: 19473640
[TBL] [Abstract][Full Text] [Related]
27. Rare case of spot diagnosis of nephrotic syndrome in a Saudi male.
Askar A; Mushtaq F; Al Shuaibi F; Mustafa M; Bappu A
Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):1003-7. PubMed ID: 21912033
[TBL] [Abstract][Full Text] [Related]
28. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
29. Crescentic glomerulonephritis developing in the course of idiopathic membranoproliferative glomerulonephritis.
Sharma A; Gupta R; Lal C; Agarwal SK; Dinda AK
Saudi J Kidney Dis Transpl; 2013 Mar; 24(2):333-7. PubMed ID: 23538361
[TBL] [Abstract][Full Text] [Related]
30. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab.
Alfakeeh K; Azar M; Alfadhel M; Abdullah AM; Aloudah N; Alsaad KO
Pediatr Nephrol; 2017 May; 32(5):885-891. PubMed ID: 28210841
[TBL] [Abstract][Full Text] [Related]
31. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
[TBL] [Abstract][Full Text] [Related]
32. [The course and prognosis of mesangioproliferative glomerulonephritis].
Shilov EM; Tareeva IE; Ivanov AA; Troepol'skaia OV; Krasnova TN; Varshavskiĭ VA; Proskurneva EP; Ivanova LV; Khudova IIu; Miroshnichenko NG
Ter Arkh; 2002; 74(6):11-8. PubMed ID: 12136475
[TBL] [Abstract][Full Text] [Related]
33. Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children.
Davis AE; Schneeberger EE; Grupe WE; McCluskey RT
Clin Nephrol; 1978 May; 9(5):184-93. PubMed ID: 657595
[TBL] [Abstract][Full Text] [Related]
34. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy.
Morales JM; Kamar N; Rostaing L
Contrib Nephrol; 2012; 176():10-23. PubMed ID: 22310777
[TBL] [Abstract][Full Text] [Related]
35. Inherited factor H dysfunction and complement-associated glomerulonephritis in renal grafts of first and second transplantations.
Watanabe S; Yamaguchi Y; Suzuki T; Ikezoe M; Matsumoto N; Chikamoto H; Nagafuchi H; Horita S; Hattori M; Shiraga H; Tokumoto T; Tanabe K; Toma H; Ito K
Clin Transplant; 2001; 15 Suppl 5():45-50. PubMed ID: 11791795
[TBL] [Abstract][Full Text] [Related]
36. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
37. Allelic variants of complement genes associated with dense deposit disease.
Abrera-Abeleda MA; Nishimura C; Frees K; Jones M; Maga T; Katz LM; Zhang Y; Smith RJ
J Am Soc Nephrol; 2011 Aug; 22(8):1551-9. PubMed ID: 21784901
[TBL] [Abstract][Full Text] [Related]
38. Membranous nephropathy: when and how to treat.
Lai KN
Kidney Int; 2007 May; 71(9):841-3. PubMed ID: 17457329
[TBL] [Abstract][Full Text] [Related]
39. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Rudnicki M
Biomed Res Int; 2017; 2017():2180508. PubMed ID: 28573137
[TBL] [Abstract][Full Text] [Related]
40. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease.
Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC
Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
